header image

Page 52«..1020..51525354..6070..»

Characterization and Immunomodulation of Canine Amniotic Membrane Stem | SCCAA – Dove Medical Press

Alessandra de Oliveira Pinheiro,1 Valria M Lara,1 Aline F Souza,1 Juliana B Casals,2 Fabiana F Bressan,1 Paulo Fantinato Neto,1 Vanessa C Oliveira,1 Daniele S Martins,1 Carlos E Ambrosio1

1Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of So Paulo, Pirassununga, So Paulo, Brazil; 2Private Veterinary Practice, Pirassununga, So Paulo, Brazil

Correspondence: Carlos E AmbrosioDepartment of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of So Paulo, FZEA- Av. Duque de Caxias Norte, 225, ZMV, Pirassununga 13635-900, So Paulo, BrazilTel +55 19 3565-4113 Email ceambrosio@usp.br

Purpose: Amniotic membrane stem cells have a high capacity of proliferation, cell expansion, and plasticity, as well as immunomodulatory properties that contribute to maternal-fetal tolerance. Owing to the lack of research on human amniotic membrane at different gestational stages, the canine model is considered ideal because of its genetic and physiological similarities. We aimed to characterize the canine amniotic membrane (CAM) cell lineage in different gestational stages and evaluate the expression of immunomodulatory genes.Materials and Methods: Twenty CAMs from early (20 30 days) (n=7), mid- (31 45 days) (n=7), and late gestation (46 63 days) (n=6) stages were studied. The cell features were assessed by cell viability tests, growth curve, colony-forming units, in vitro differentiation, cell labeling for different immunophenotypes, and pluripotent potential markers. The cells were subjected to RT-PCR and qPCR analysis to determine the expression of IDO, HGF, EGF, PGE2, and IL-10 genes.Results: CAM cells exhibited a fibroblastoid morphology and adherence to plastic with an average cell viability of 78.5%. The growth curve indicated a growth peak in the second passage and we obtained an average of 138.2 colonies. Osteogenic, chondrogenic, and adipogenic lineages were confirmed by in vitro differentiation assays. Cellular immunophenotyping experiments confirmed the presence of positive mesenchymal markers (CD90 and CD105) and the low or negative expression of hematopoietic markers (CD45 and CD34). Qualitative analysis of the immunomodulatory functions indicated the expression of the IDO, HGF, EGF5, and PGE2 genes. When stimulated by interferon-gamma, CAM cells exhibited higher IDO levels throughout gestation.Conclusion: The CAMs from different gestational stages presented features consistent with mesenchymal stem cell lineage; better results were observed during the late gestation stage. Therefore, the gestational stage is a key factor that may influence the functionality of therapies when using fetal membrane tissues from different periods of pregnancy.

Keywords: canine stem cells, immunomodulation, fetal annexes

This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/.The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Read this article:
Characterization and Immunomodulation of Canine Amniotic Membrane Stem | SCCAA - Dove Medical Press

Stem Cell Therapy For Dogs – Treat Dog Arthritis & Joint …

1. Veterinarian consultation.

Visit your veterinarian to ensure that Stem Cell Therapy is suitable for a particular case. Veterinarians will decide whether to use autologous or allogeneic Stem Cells.

If your veterinarian is not aware of such treatment options as stem cell therapy, we will be happy to assist him and explain more about the opportunities he is missing out. For most popular horse injuries Stem Cells do appear to be the most effective treatment option available.

2. Ordering Stem Cell Therapy.

Veterinarian or Dog owner can easily order the CaniCell therapy over the phone, email or order form and it will be delivered to your desired clinic on dry ice within 24-48 hours. A veterinarian can also easily store the treatment doses in a regular freezer (-20C ) for future use or upcoming cases.

3. Performing the Stem Cell Therapy.

A veterinarian will perform a Stem Cell Therapy, that includes local short-term anesthesia and simple Stem Cell injection guided by ultrasound.

In the case of intravenous (IV) injection for overall improvements and performance boost, it will be even easier, just a simple injection in the bloodstream.

4. Recovery and observation.

After the procedure, follow veterinarian instructions and see how your dog recovers and thrives. The complete recovery takes 3-6 months, but the first effect can be already seen earlier.

Originally posted here:
Stem Cell Therapy For Dogs - Treat Dog Arthritis & Joint ...

Canine Stem Cell Therapy Market To Extend An Assessed Value Of US$ 218.2 Mn By 2026 – Cole of Duty

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Regions Covered In Report

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

View original post here:
Canine Stem Cell Therapy Market To Extend An Assessed Value Of US$ 218.2 Mn By 2026 - Cole of Duty

Schizophrenia drug combined with radiation shows promise in treating deadly brain tumours, says study – Free Press Journal

Washington: A recent study has suggested that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumours.

The findings of the study conducted by researchers at the UCLA Jonsson Comprehensive Cancer Center and colleagues was published in the journal 'Proceedings of the National Academy of Sciences'.

It shows that a combination of radiation and the drug trifluoperazine not only targets glioblastoma cells but also helps overcome the resistance to treatment so common to this aggressive form of cancer. The results could prove promising for patients with the disease, for whom the median survival time is only 12 to 18 months following diagnosis.

Radiation is an integral part of therapy for people with cancer and one of the most effective treatments. In many cases, it can help cure the disease. But in glioblastoma, tumour cells often become resistant to radiation treatment because the radiation itself can induce "phenotype conversion," a process that turns certain non-tumour stem cells into tumour-producing cells, causing cancer to reoccur.

"While radiotherapy is one of the few treatments that prolong survival in glioblastoma patients, radiation alone does very little in treating the disease in our models because we are dealing with highly aggressive tumours," said the study's senior author, Dr Frank Pajonk, a professor of radiation oncology at the David Geffen School of Medicine at UCLA and a member of the Jonsson Cancer Center.

"The drug trifluoperazine by itself does not do much either, but we found when you combine them, they become highly efficient. Importantly, the drug does not sensitise cells to radiation but rather prevents the occurrence of resistant glioma stem cells," Pajonk added.

UCLA researchers have been exploring new ways to prevent glioblastoma tumour cells from becoming resistant to radiation by adding drugs to the treatment regimen that have traditionally been used for other purposes.

To find out if there were any existing drugs that could interfere with the radiation-induced phenotype conversion, the team screened more than 83,000 compounds through the shared resources at UCLA, which provides researchers access to specialised equipment and services to help them pursue cutting-edge research.

They were able to identify nearly 300 compounds, including the dopamine receptor antagonist trifluoperazine, that had the potential to block phenotype conversion and improve the efficacy of radiation therapy.

Once trifluoperazine was identified, it was tested on mice with patient-derived orthotopic tumours. The team found that when used in combination with radiation, trifluoperazine successfully delayed the growth of the tumours and significantly prolonged the overall survival of the animals.

Combining radiation treatment with trifluoperazine extended survival in 100 per cent of the mice to more than 200 days, compared to 67.7 days in the control group receiving only radiation.

"Many preclinical glioblastoma studies report fairly small increases in overall survival in mice, and that rarely translates into benefits for patients," said Pajonk, who is also a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

"But here, we see pretty drastic effects in improved overall survival and I find that very encouraging. It gives us hope that this is all going to translate into a benefit for people," Pajonk further said.

The team plans to start a clinical trial this summer for people with recurrent glioblastoma to test using dopamine receptor antagonist with radiation therapy.

"I think we can find a combination of treatments with radiation that is very tolerable to patients and can do well," said co-author Leia Nghiemphu, an associate professor of clinical neurology at the Geffen School of Medicine and principal investigator on the upcoming clinical trial. "The next step is to see if we can stop this resistance to radiation in humans," added Nghiemphu.

View post:
Schizophrenia drug combined with radiation shows promise in treating deadly brain tumours, says study - Free Press Journal

NJ business survey: Reopening and surviving aren’t the same thing – wobm.com

If New Jersey businesses were given the green light to open their doors and operate under social distancing guidelines, most owners in the state believe they could follow the rules but making enough money to survive is another story.

In a New Jersey Business & Industry Association survey of its members, more than 50% of the 1,359 respondents said they would need at least 75% of their typical customer/client base in order to break even in a given month.

If a partial reopening 50%, the NJBIA survey assumes of a restaurant or shop were granted permission to open once again to the public, 21% of businesses believe they'd never be able to generate a profit. On the other hand, 50% of businesses believe their revenues can reach pre-COVID-19 profits within a year.

The survey didn't specifically ask businesses whether or not they would open the doors if granted permission by the state, but 70% of owners said they're able to operate safely under CDC social distancing guidelines customers remaining 6 feet away from others, for example.

"Reopening is one thing, sustainability is another," said NJBIA President and CEO Michele Siekerka. "I think it's safe to say that there will be a numerous businesses, that if they can't open to a certain capacity, they're not going to be able to open."

Opening to the public in a way that accommodates rules meant to stem the spread of COVID-19, Siekerka noted, could mean capital improvements for certain businesses, such as added barriers or changes to the way customers enter and exit. A reopening will likely also include the need for employees to wear personal protective equipment, which is an added expense. Businesses will be "doubling down" on sanitizing efforts as well, she added.

"They want to present an environment that is going to be viewed and observed as being a safe place to be, so that they garner the credibility for people to come back," Siekerka said.

NJBIA's Business Recovery Survey was conducted between April 23 and 28. At that time, 74% of surveyed employers had applied for the federal Paycheck Protection Program. Of that group, 65% said they had not yet received their funding that helps pay for payroll costs, rent and other business-related expenses.

Meanwhile, 78% percent of businesses who applied for a Small Business Emergency grant or loan from the New Jersey Economic Development Authority had not received their funds.

"Meeting payroll costs" was sited among employers as the top struggle for their businesses, followed by "paying the rent," "ensuring worker safety," and "repaying existing loans on time."

Siekerka said the NJBIA continues to advocate for more flexibility within the PPP to assist businesses not only during their closure or slowdown, but in their recovery mode as well.

When asked what percentage of their typical in-person workforce is needed in order to operate productively, 27% of employers said they'd need 100% of their workers. Another 15% said they'd need at least 75% of their workforce to get the job done.

Follow this link:
NJ business survey: Reopening and surviving aren't the same thing - wobm.com

Assessing the Fallout From the Coronavirus Pandemic Value of Canine Stem Cell Therapy Market Predicted to Surpass US$ by the of 20512019-2019 -…

Given the debilitating impact of COVID-19 (Coronavirus) on the Canine Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Canine Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Canine Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Canine Stem Cell Therapy market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Canine Stem Cell Therapy market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Canine Stem Cell Therapy market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

Regional Overview

Our team of analysts at PMR, trace the major developments within the Canine Stem Cell Therapy landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Canine Stem Cell Therapy market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

Key Takeways Enclosed in the Report:

Queries Related to the Canine Stem Cell Therapy Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Why Opt for Persistence Market Research?

Visit link:
Assessing the Fallout From the Coronavirus Pandemic Value of Canine Stem Cell Therapy Market Predicted to Surpass US$ by the of 20512019-2019 -...

The problem with hunting and farming animals, Asia News & Top Stories – The Straits Times

By now, Covid-19 is humanity's Public Enemy No. 1 and governments are working furiously to contain its spread. In our part of the world, in a recent Special Asean Plus Three Summit, the leaders of the Asean nations, China, South Korea and Japan met via video conference to mount a collective health and economic response.

That's an admirable united stand in stark contrast to United States President Donald Trump's vitriolic blame-and-shame attack on China and the World Health Organisation.

I absolutely reject conspiracy theories that the coronavirus was made in a Wuhan laboratory and was somehow released, or that it is a Big Pharma sinister plot to push a panicked world into developing a vaccine that would bring in millions of dollars in profits.

What I do accept is that Covid-19 is man-made in the sense of how we have brought it upon ourselves because of our population explosion and food demands, specifically for meat.

Viruses, like bacteria, are very much part of just about everything, and just as there are good and bad bacteria, there are good and bad viruses. (I was gobsmacked to learn that if not for a virus, mammals, including humans, would still be laying eggs! You can find out more from the National Public Radio podcast How The Placenta Evolved From An Ancient Virus.)

In H.G. Wells' 1898 science-fiction novel, The War Of The Worlds, a virus (or bacterium) was humankind's saviour because it killed the Martian invaders, which had no immunity to the microbe.

Wells wrote: "These germs of disease have taken toll of humanity since the beginning of things - taken toll of our pre-human ancestors since life began here. But by virtue of this natural selection of our kind we have developed resisting power; to no germs do we succumb without a struggle."

Indeed, humankind must have had many epic struggles with viruses because scientists have discovered that significant chunks of the human DNA are remnants of ancient viral infections.

Through the aeons, we have encountered many zoonoses - diseases caused by viruses or bacteria that jump from animals or insects to humans - that include rabies, anthrax, the plague, malaria, dengue, Zika, avian flu and swine influenza.

So why has Covid-19 unleashed such an earth-shaking pandemic?

Infectious diseases expert Dennis Carroll, who was featured in the Netflix series Pandemic, knows why. He spent a decade leading a US-funded programme called Predict, hunting for unknown viruses in animals around the world that had the potential to emerge.

He tells Nautilus, an online science magazine: "Whatever future threats we're going to face already exist. A large pool of viruses are circulating (in wildlife) and we don't become familiar with them until we see a spillover event and people getting ill."

Studies have shown that the rate of spillovers has jumped two to three times in the last 40 years and is still increasing because "the frequency of interaction between people and wildlife is happening at a scale never before seen", says Dr Carroll.

"We've calculated based on historical evidence that we're looking at two to four new zoonotic disease threats emerging every year. So, it should not come as a surprise that today, we're talking about the Covid-19 virus."

He points out that 100 years ago, there were only 1.8 billion people on earth. Today, the figure is almost eight billion.

"With that comes all of the livestock and animal production to feed the human population. We've expanded our cities, our settlements, our agriculture into wildlife areas," he says in another interview with Kaiser Health News.

Dr Carroll cites the avian influenza in the 2000s as a direct consequence of how much poultry was being produced to feed people.

Today, China alone produces 15 billion to 20 billion poultry per year. Compare that with the few hundred million poultry produced in the 1960s.

It's the same virus-friendly meat-producing scenario replayed across the globe which is a consequence of more people and more purchasing power.

"One of the things we know about household purchasing power is that when you have disposable income, you're going to move from a root-or grain-based diet and try to get animal protein," says Dr Carroll.

He estimates there are 1.67 million viruses on earth, of which 631,000 to 827,000 have the potential to infect people.

So, if we hope to avert another global pandemic, we must eliminate existing zoonotic flashpoints and not just develop vaccine after vaccine.

That's why I support Good Food Institute's science and technology associate director Liz Specht's call for a reinvention of how we grow and slaughter meat.

As she opines in a Wired article: "Governments are pouring immense resources into therapeutic and vaccine development programmes in a frantic attempt at damage control for the current outbreak. But none of this will prevent the next, and potentially even worse, pandemic."

Instead, she says: "It's time to admit that we, as a civilisation, have outgrown the dated notion of using animals to produce meat. Hunting and animal farming served their purpose for millennia of human population growth.

"But in 2020, we need to be brutally honest with ourselves. We can't keep doing this. The current system is broken. It is inefficient, insecure, unsustainable and extremely unsafe."

She adds that the solution is already available: moving to plant-based and cultivated-from-cells meat products which can remove the food insecurity and zoonotic disease concerns inherent in animal-based food.

We can expect horrified protests from the anti-GMO (genetically modified organisms) activists who cannot accept the fact that practically every single plant and animal we humans eat has had its genes altered through selective breeding and hybridisation by farmers and scientists.

Despite such objections, I think the "clean meat" revolution, as it has been dubbed, will take off because there is growing public acceptance of alternatives and rising revulsion against rearing and slaughtering animals for meat.

Besides, as Dr Specht says, the joy of eating meat is increasingly recognised as a sensory experience brought about by the combination of specific amino acids, fats and minerals rather than by its means of production.

Therefore, she adds: "No animal has to be farmed or hunted and no disease has to be risked to enjoy a juicy burger or a crispy nugget."

The United Nations has already stated that raising and killing animals for food is "one of the major causes of the world's most pressing environmental problems".

We saw how in just 100-plus days of the Covid-19 pandemic, when the world practically came to a stop, our environment - especially air quality - improved drastically.

My hope is that governments will not only ban wildlife trafficking and exotic meat markets, but also see the sense in putting in place the funding, legislation, safety standards, infrastructure and public education for clean meat.

Dr Specht likens the draconian lockdown measures and travel restrictions against Covid-19 to shutting the barn doors after the horses have bolted.

So, rather than repeating the same mistake of trying to close the doors after the horses have run off, she says, we need to build a better barn. I would add we had better do it fast as the Covid clock is ticking.

The writer is the former group chief editor of Star Media Group. The paper is a member of The Straits Times' media partner Asia News Network, an alliance of 24 news media titles.

See the original post here:
The problem with hunting and farming animals, Asia News & Top Stories - The Straits Times

Are you an essential worker in Texas? Check out this list of critical infrastructure jobs – Standard-Times

John Tufts, San Angelo Standard-Times Published 7:20 p.m. CT April 24, 2020

Mark Pilon sprays disinfectant on a bus in the Concho Valley Transit fleet on Wednesday, March 18, 2020 as an enhanced measure against the coronavirus.(Photo: Colin Murphey / San Angelo Standard-Times)

Governor Greg Abbott announced April 17the Texas economy would reopen in stagesafter weeks of being shut down due to the coronavirus.

"Some businesses, if fully open without better distancing standards, would be more likely to set us back, rather than propel us forward," Abbott said April 17. "A more strategic approach is required to ensure we don't reopen only to have to shut down again."

On April 24, 2020, stores in the state will be allowed to reopen usinga "retail to-go" model, Abbott said. Reopened retailers willdeliver goods to customers' cars or homes, but customerswill not be able to go inside the stores.

Abbott said additional openings will be announced April 27after further input from advisers and medical professionals.

While Texas residents wait for officials to bring the state's economy fully back to life, the Texas Division of Emergency Management (TDEM) continues to maintain an online list of essential services.

The list TDEM uses is based off recommendations by the Department of Homeland Security under 17 categories, which are:

On March 28, 2020, officials with the the Cybersecurity and Infrastructure Security Agency (CISA),in collaboration with other federal, State and local governments, as well as the private sector, developedan Essential Critical Infrastructure Workforce advisory list.

CISA Director Christopher C. Krebs said the list is advisory in nature.

"It is not, nor should it be considered, a federal directive or standard. Additionally, this advisory list is not intended to be the exclusive list of critical infrastructure sectors, workers, and functions that should continue during the COVID-19 response across all jurisdictions," Krebs stated.

Officials said local jurisdictions should add or subtract essential workforce categories based on their own requirements and discretion.

Electricity Industry

Petroleum Industry

Natural Gas, Natural Gas Liquids (NGL), Propane, and Other Liquid Fuels

Communications

Information Technology

More: OPINION: Texas leaders pen letter demanding expansion of Medicaid amid COVID-19 pandemic

John Tufts covers enterprise and investigative topics in West Texas. Send him a news tip atJTufts@Gannett.com. Consider supporting West Texas journalism with asubscription toGoSanAngelo.com.

Read or Share this story: https://www.gosanangelo.com/story/news/2020/04/24/essential-worker-texas-check-list-critical-jobs-critical-infrastructure-workforce/3012617001/

Read the original here:
Are you an essential worker in Texas? Check out this list of critical infrastructure jobs - Standard-Times

Increasing Consumer Adoption During COVID-19 Crisis to Increase Demand for Canine Stem Cell Therapy Market in Next Ten Years – Jewish Life News

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Regions Covered In Report

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness aCAGR of 4.2%during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation ofUS$ 218.2 Mnby the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Read more:
Increasing Consumer Adoption During COVID-19 Crisis to Increase Demand for Canine Stem Cell Therapy Market in Next Ten Years - Jewish Life News

Social distancing could be in place for up to a year, says chief medical officer – Telegraph.co.uk

The Government said at the beginning of April it wanted to be testing 100,000 people a day for coronavirus.

The capacity today is just 40,000 tests a day.

But the reality is that yesterday only 18,000 tests were carried out.

Social Care Minister Helen Whately told the Today programme: "It clearly is really troubling when strategy is to increase testing capacity and get as much testing happening as possible.

"We have had a huge increase - up to now we've had a capacity of 40,000 tests a day, but in practice yesterday we did about 18,000."

Asked how the Government is addressing the shortfall, she said: "One thing we're looking at is access to tests.

"In social care, they've offered drive through centres but not everybody has access to a car.

"So we have started using mobile testing units, which have worked well so far so we'll be doing more of that.

"And home testing kits - you get a home testing kit delivered to your home."

See more here:
Social distancing could be in place for up to a year, says chief medical officer - Telegraph.co.uk

Back to Top